143 related articles for article (PubMed ID: 30039885)
1. TRIM65 is a potential oncogenic protein via ERK1/2 on Jurkat and Raji cells: A therapeutic target in human lymphoma malignancies.
Wang J; Liang X; Yu T; Xu YL; Xu LH; Zhang XJ; Ma J; Wang YR; He SL
Cell Biol Int; 2018 Nov; 42(11):1503-1510. PubMed ID: 30039885
[TBL] [Abstract][Full Text] [Related]
2. [Effect of ERK1/2 inhibitor AZD8330 on human Burkitt's lymphoma cell line Raji cells and its mechanism].
Feng K; Wang C; Zhou H; Yang J; Dong L; Zhou K; Liu X; Song Y
Zhonghua Xue Ye Xue Za Zhi; 2015 Feb; 36(2):148-52. PubMed ID: 25778893
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of TRIM65 inhibits lung cancer cell proliferation, migration and invasion: A therapeutic target in human lung cancer.
Wang XL; Shi WP; Shi HC; Lu SC; Wang K; Sun C; He JS; Jin WG; Lv XX; Zou H; Shu YS
Oncotarget; 2016 Dec; 7(49):81527-81540. PubMed ID: 27829229
[TBL] [Abstract][Full Text] [Related]
4. TRIM65 Promotes Invasion of Endometrial Stromal Cells by Activating ERK1/2/C-myc Signaling via Ubiquitination of DUSP6.
Wu YT; Ma SY; Sun WQ; Shen WW; Zhu HT; Zhang Q; Chen HF
J Clin Endocrinol Metab; 2021 Jan; 106(2):526-538. PubMed ID: 33146694
[TBL] [Abstract][Full Text] [Related]
5. TRIM65 triggers β-catenin signaling via ubiquitylation of Axin1 to promote hepatocellular carcinoma.
Yang YF; Zhang MF; Tian QH; Zhang CZ
J Cell Sci; 2017 Sep; 130(18):3108-3115. PubMed ID: 28754688
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of Tripartite Motif-Containing 48 (TRIM48) Inhibits Growth of Human Glioblastoma Cells by Suppressing Extracellular Signal Regulated Kinase 1/2 (ERK1/2) Pathway.
Xue LP; Lu B; Gao BB; Shi YY; Xu JQ; Yang R; Xu B; Ding P
Med Sci Monit; 2019 Nov; 25():8422-8429. PubMed ID: 31703057
[TBL] [Abstract][Full Text] [Related]
7. Expression and the potential functions of TRIM32 in lung cancer tumorigenesis.
Yin H; Li Z; Chen J; Hu X
J Cell Biochem; 2019 Apr; 120(4):5232-5243. PubMed ID: 30378152
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of TRIM65 suppressed the proliferation and invasiveness of gastric cancer cells by restricting the ubiquitin degradation of PPM1A.
Liu C; Sun W; Yang K; Xia B
Exp Cell Res; 2022 Jul; 416(2):113154. PubMed ID: 35421368
[TBL] [Abstract][Full Text] [Related]
9. Combinatory inhibition of TRIM65 and MDM2 in lung cancer cells.
Chen G; Zhou T; Liu Y; Yu Z
Biochem Biophys Res Commun; 2018 Nov; 506(3):698-702. PubMed ID: 30454706
[TBL] [Abstract][Full Text] [Related]
10. TRIM65 negatively regulates p53 through ubiquitination.
Li Y; Ma C; Zhou T; Liu Y; Sun L; Yu Z
Biochem Biophys Res Commun; 2016 Apr; 473(1):278-282. PubMed ID: 27012201
[TBL] [Abstract][Full Text] [Related]
11. Tripartite motif-containing protein 7 regulates hepatocellular carcinoma cell proliferation via the DUSP6/p38 pathway.
Hu X; Tang Z; Ma S; Yu Y; Chen X; Zang G
Biochem Biophys Res Commun; 2019 Apr; 511(4):889-895. PubMed ID: 30850165
[TBL] [Abstract][Full Text] [Related]
12. TRIM65 supports bladder urothelial carcinoma cell aggressiveness by promoting ANXA2 ubiquitination and degradation.
Wei WS; Chen X; Guo LY; Li XD; Deng MH; Yuan GJ; He LY; Li YH; Zhang ZL; Jiang LJ; Chen RX; Ma XD; Wei S; Ma NF; Liu ZW; Luo JH; Zhou FJ; Xie D
Cancer Lett; 2018 Oct; 435():10-22. PubMed ID: 30075204
[TBL] [Abstract][Full Text] [Related]
13. TRIM65 knockout inhibits the development of HCC by polarization tumor-associated macrophages towards M1 phenotype via JAK1/STAT1 signaling pathway.
Jiang M; Wang D; Su N; Lou W; Chen Y; Yang H; Chen C; Xi F; Chen Y; Deng L; Tang X
Int Immunopharmacol; 2024 Feb; 128():111494. PubMed ID: 38218012
[TBL] [Abstract][Full Text] [Related]
14. Exogenous hydrogen sulfide promotes C6 glioma cell growth through activation of the p38 MAPK/ERK1/2-COX-2 pathways.
Zhen Y; Zhang W; Liu C; He J; Lu Y; Guo R; Feng J; Zhang Y; Chen J
Oncol Rep; 2015 Nov; 34(5):2413-22. PubMed ID: 26351820
[TBL] [Abstract][Full Text] [Related]
15. TRIM11 promotes lymphomas by activating the β-catenin signaling and Axin1 ubiquitination degradation.
Hou Y; Ding M; Wang C; Yang X; Ye T; Yu H
Exp Cell Res; 2020 Feb; 387(2):111750. PubMed ID: 31786079
[TBL] [Abstract][Full Text] [Related]
16. [Effect of AZD8330 on proliferation and apoptosis of multiple myeloma cells].
Yao Y; Bian YP; Xia DD; Pan B; Niu MS; Zhao K; Zeng LY; Xu KL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1311-5. PubMed ID: 25338579
[TBL] [Abstract][Full Text] [Related]
17. [Expression of Notch signal molecules in human lymphoma cells and its significance].
Wang YF; Li YY; Wang J; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):83-7. PubMed ID: 22391171
[TBL] [Abstract][Full Text] [Related]
18. [Effects of mTOR Inhibitor Rapamycin on Burkitt's Lymphoma Cells].
Zhou LH; Zhu XP; Xiao HF; Xin PL; Li CT
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1397-1405. PubMed ID: 29070114
[TBL] [Abstract][Full Text] [Related]
19. Triptonide acts as a novel potent anti-lymphoma agent with low toxicity mainly through inhibition of proto-oncogene Lyn transcription and suppression of Lyn signal pathway.
Yang P; Dong F; Zhou Q
Toxicol Lett; 2017 Aug; 278():9-17. PubMed ID: 28666825
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic HSP60 regulates mitochondrial oxidative phosphorylation to support Erk1/2 activation during pancreatic cancer cell growth.
Zhou C; Sun H; Zheng C; Gao J; Fu Q; Hu N; Shao X; Zhou Y; Xiong J; Nie K; Zhou H; Shen L; Fang H; Lyu J
Cell Death Dis; 2018 Feb; 9(2):161. PubMed ID: 29415987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
